Manufacturers report improved outcomes in patients with advanced hepatocarcinoma given cabozantinib vs regorafenib in match-adjusted comparison of trials

In a matching-adjusted indirect comparison of results from the Phase III CELESTIAL and RESORCE trials, cabozantinib showed a superior progression free survival vs regorafenib when given after failure of sorafenib (5.6 months vs 3.1 months).


Biospace Inc.